Loading…
To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
This bill requires the Centers for Medicare & Medicaid Services to pay, to a provider that furnishes a hematopoietic stem cell transplant, an adjusted Medicare payment consistent with the Medicare payment methodology for kidney-acquisition costs outlined in regulation. Under the applicable regulation, kidney-acquisition costs are treated apart from the prospective payment rate for inpatient operating costs, and payment is adjusted to compensate the hospital for certain reasonable expenses. "Hematopoietic stem cell transplant" means the infusion of allogeneic hematopoietic cells (including bone marrow, peripheral blood stem cells, and cord-blood units, but excluding embryonic stem cells) that are: (1) not more than minimally manipulated; and (2) intended to reestablish hematopoietic function in an individual whose blood marrow or immune system is damaged, defective, or adversely affective by a congenital disorder.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · fourth_quarter · Medicare/Medicaid
Inpatient hospital prospective payment system proposed and final rule; hospital outpatient prospective payment system proposed rule; HR 4215, Protect Access to Cellular Transplantation Act; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018); FY 2019 Labor-HHS Appropriations
Referred to the House Committee on Ways and Means.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · fourth_quarter · Medicare/Medicaid
CMS reimbursement for CAR-T and immunotherapies Protect Access to Cellular Transplant (PACT) Act (H.R. 4215) Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Medicare/Medicaid
Monitor the following: H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes, Organ bone marrow transplant issues Medicaid 1115 Waiver H.R.5985, To amend title XVIII of the Social Security Act to permit review of certain Medicare payment determinations for disproportionate share hospitals, and for other purposes, Medicare appeal issues
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes (Protect Access to Cellular Transplant "PACT", Medicare reimbursement issues.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2018 · third_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes, Monitor organ bone marrow transplant issues Monitor Medicaid 1115 Waiver H.R.5985, To amend title XVIII of the Social Security Act to permit review of certain Medicare payment determinations for disproportionate share hospitals, and for other purposes, Medicare appeal issues
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Medicare/Medicaid
hospital inpatient and outpatient prospective payment system; HR 4215 The Protect Access to Cellular Transplants Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Medicare/Medicaid
Inpatient hospital prospective payment system proposed and final rule; hospital outpatient prospective payment system proposed rule; HR 4215, Protect Access to Cellular Transplantation Act; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018); FY 2019 Labor-HHS Appropriations
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · third_quarter · Medicare/Medicaid
CMS reimbursement for CAR-T Protect Access to Cellular Transplant (PACT) Act (H.R. 4215) Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) CMS National Coverage Determinations Medicaid Coverage for Sickle Cell Disease Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes (Protect Access to Cellular Transplant "PACT", Medicare reimbursement issues.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medicare/Medicaid
hospital inpatient and outpatient prospective payment system; HR 4215 The Protect Access to Cellular Transplants Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medicare/Medicaid
Inpatient hospital prospective payment system proposed and final rule; hospital outpatient prospective payment system proposed rule; HR 4215, Protect Access to Cellular Transplantation Act; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018); FY 2019 Labor-HHS Appropriations
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · second_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes, Organ bone marrow transplant issues Monitor Medicaid 1115 Waiver
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medicare/Medicaid
CMS reimbursement for CAR-T Protect Access to Cellular Transplant (PACT) Act (H.R. 4215) Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) CMS National Coverage Determinations Medicaid Coverage for Sickle Cell Disease Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes (Protect Access to Cellular Transplant "PACT", Medicare reimbursement issues.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · first_quarter · Medicare/Medicaid
hospital inpatient and outpatient prospective payment system; HR 4215 The Protect Access to Cellular Transplants Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medicare/Medicaid
Inpatient hospital prospective payment system proposed and final rule; hospital outpatient prospective payment system proposed rule; HR 4215, Protect Access to Cellular Transplantation Act; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018)
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · first_quarter · Medicare/Medicaid
Protect Access to Cellular Transplant (PACT) Act (H.R. 4215) Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) CMS National Coverage Determination Medicaid Coverage for Sickle Cell Disease
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes (Protect Access to Cellular Transplant "PACT", Medicare reimbursement issues.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
hospital inpatient and outpatient prospective payment system; HR 4215 The Protect Access to Cellular Transplants Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
Inpatient hospital prospective payment system proposed and final rule; hospital outpatient prospective payment system proposed rule; HR 4215, Protect Access to Cellular Transplantation Act
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2017 · fourth_quarter · Medicare/Medicaid
Protect Access to Cellular Transplant (PACT) Act (H.R. 4215) Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (P.L. 114-10) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628) Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform Bipartisan Health Care Stabilization Act (proposed by Senators Alexander and Murray) CMS National Coverage Determination Medicaid Coverage for Sickle Cell Disease
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · fourth_quarter · Medicare/Medicaid
H.R.4215, To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes (Protect Access to Cellular Transplant "PACT", Medicare reimbursement issues.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
H.R. 4215 (Protect Access to Cellular Transplant (PACT) Act), which would require Medicare to make separate payments to hospitals to cover costs associated with donor search and acquisition for hematopoietic cell transplantation.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medicare/Medicaid
H.R. 4215 (Protect Access to Cellular Transplant (PACT) Act), which would require Medicare to make separate payments to hospitals to cover costs associated with donor search and acquisition for hematopoietic cell transplantation.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| NJ |
| Collin C. Peterson | Democratic | MN |
| Dennis A. Ross | Republican | FL |
| Doris O. Matsui | Democratic | CA |
| Earl Blumenauer | Democratic | OR |
| Elizabeth H. Esty | Democratic | CT |
| Gus M. Bilirakis | Republican | FL |
| John Lewis | Democratic | GA |
| Joyce Beatty | Democratic | OH |
| Kenny Marchant | Republican | TX |
| Lynn Jenkins | Republican | KS |
| Mike Thompson | Democratic | CA |
| Patrick Meehan | Republican | PA |
| Peter A. DeFazio | Democratic | OR |
| Peter J. Roskam | Republican | IL |
| Richard Hudson | Republican | NC |
| Ro Khanna | Democratic | CA |
| Roger Marshall | Republican | KS |
| Ron Kind | Democratic | WI |
| Salud O. Carbajal | Democratic | CA |
| Thomas J. Rooney | Republican | FL |
| Tom Emmer | Republican | MN |
| Zoe Lofgren | Democratic | CA |